Search research articles
Contact Us
Filters
Showing results (51-60 of 278) with videos related to
Page
of 28
Sort By:
Scientific Reports
|
June 16, 2017
A sex-specific reconstitution bias in the competitive CD45.1/CD45.2 congenic bone marrow transplant model
Salema Jafri, Stephen D Moore, Nicholas W Morrell, et al.
Molecular Pharmacology
|
November 9, 2007
Functional characterization of bone morphogenetic protein binding sites and Smad1/5 activation in human vascular cells
Paul D Upton, Lu Long, Richard C Trembath, et al.
Pulmonary Circulation
|
December 6, 2011
The world of pulmonary vascular disease
Jason X-J Yuan, Nicholas W Morrell, S Harikrishnan, et al.
Global Cardiology Science & Practice
|
January 19, 2016
The promise of recombinant BMP ligands and other approaches targeting BMPR-II in the treatment of pulmonary arterial hypertension
Mark L Ormiston, Paul D Upton, Wei Li, et al.
The Journal of Biological Chemistry
|
April 16, 2009
Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells
Paul D Upton, Rachel J Davies, Richard C Trembath, et al.
Scientific Reports
|
September 19, 2019
A Bone Morphogenetic Protein (BMP)-derived Peptide Based on the Type I Receptor-binding Site Modifies Cell-type Dependent BMP Signalling
Zhen Tong, Jingxu Guo, Robert C Glen, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology
|
November 2, 2004
BMP4 inhibits proliferation and promotes myocyte differentiation of lung fibroblasts via Smad1 and JNK pathways
Trina K Jeffery, Paul D Upton, Richard C Trembath, et al.
American Journal of Respiratory and Critical Care Medicine
|
June 3, 2014
Better off blue: BMPR-2 mutation, arteriovenous malformation, and pulmonary arterial hypertension
Elaine Soon, Mark Southwood, Karen Sheares, et al.
Human Molecular Genetics
|
May 22, 2024
Functional validation of EIF2AK4 (GCN2) missense variants associated with pulmonary arterial hypertension
Giulia Emanuelli, JiaYi Zhu, Wei Li, et al.
Pulmonary Pharmacology & Therapeutics
|
July 6, 2010
Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension
Frank Reichenberger, Ann Mainwood, Nicholas W Morrell, et al.
Page
of 28
Search research articles
Search
Showing results (51-60 of 278) with videos related to
Sort By:
Page
of 28
Scientific Reports
|
June 16, 2017
A sex-specific reconstitution bias in the competitive CD45.1/CD45.2 congenic bone marrow transplant model
Salema Jafri, Stephen D Moore, Nicholas W Morrell, et al.
Molecular Pharmacology
|
November 9, 2007
Functional characterization of bone morphogenetic protein binding sites and Smad1/5 activation in human vascular cells
Paul D Upton, Lu Long, Richard C Trembath, et al.
Pulmonary Circulation
|
December 6, 2011
The world of pulmonary vascular disease
Jason X-J Yuan, Nicholas W Morrell, S Harikrishnan, et al.
Global Cardiology Science & Practice
|
January 19, 2016
The promise of recombinant BMP ligands and other approaches targeting BMPR-II in the treatment of pulmonary arterial hypertension
Mark L Ormiston, Paul D Upton, Wei Li, et al.
The Journal of Biological Chemistry
|
April 16, 2009
Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells
Paul D Upton, Rachel J Davies, Richard C Trembath, et al.
Scientific Reports
|
September 19, 2019
A Bone Morphogenetic Protein (BMP)-derived Peptide Based on the Type I Receptor-binding Site Modifies Cell-type Dependent BMP Signalling
Zhen Tong, Jingxu Guo, Robert C Glen, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology
|
November 2, 2004
BMP4 inhibits proliferation and promotes myocyte differentiation of lung fibroblasts via Smad1 and JNK pathways
Trina K Jeffery, Paul D Upton, Richard C Trembath, et al.
American Journal of Respiratory and Critical Care Medicine
|
June 3, 2014
Better off blue: BMPR-2 mutation, arteriovenous malformation, and pulmonary arterial hypertension
Elaine Soon, Mark Southwood, Karen Sheares, et al.
Human Molecular Genetics
|
May 22, 2024
Functional validation of EIF2AK4 (GCN2) missense variants associated with pulmonary arterial hypertension
Giulia Emanuelli, JiaYi Zhu, Wei Li, et al.
Pulmonary Pharmacology & Therapeutics
|
July 6, 2010
Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension
Frank Reichenberger, Ann Mainwood, Nicholas W Morrell, et al.
Page
of 28